Antithrombotic treatment after left atrial appendage closure (n=29)
| Antithrombotic treatment | Discharge | 6 weeks p/LAAC | 3 months p/LAAC | 6 months p/LAAC | 1-year p/LAAC |
| AP monotherapy | 0 | 7 (24.1%) | 15 (51.7%) | 20 (69.0%) | 18 (62.2%) |
| DAPT | 2 (6.9%) | 10 (34.5%) | 4 (13.8%) | 0 | 0 |
| VKA | 1 (3.4%) | 0 | 0 | 0 | 0 |
| VKA+AP | 9 (31.0%) | 4 (13.8%) | 2 (6.9%) | 2 (6.9%) | 2 (6.9%) |
| DOAC | 5 (17.3%) | 0 | 0 | 0 | 1 (3.4%) |
| DOAC+AP | 12 (41.4%) | 8 (27.6%) | 7 (24.2%) | 5 (17.3%) | 4 (13.8%) |
| None | 0 | 0 | 0 | 1 (3.4%) | 1 (3.4%) |
| Died | 0 | 0 | 0 | 0 | 1 (3.4%) |
| Lost to follow-up | 0 | 0 | 1 (3.4%) | 1 (3.4%) | 2 (6.9%) |
AP, antiplatelet; DAPT, dual antiplatelet; DOAC, direct oral anticoagulation; p/LAAC, post left atrial appendage closure; VKA, vitamin K antagonist.